Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $37.4 million.

  • Enanta Pharmaceuticals' Cash & Equivalents fell 5561.65% to $37.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $37.4 million, marking a year-over-year decrease of 5561.65%. This contributed to the annual value of $32.3 million for FY2025, which is 1325.44% down from last year.
  • Enanta Pharmaceuticals' Cash & Equivalents amounted to $37.4 million in Q4 2025, which was down 5561.65% from $32.3 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Cash & Equivalents' 5-year high stood at $99.1 million during Q4 2021, with a 5-year trough of $4.6 million in Q2 2021.
  • Its 5-year average for Cash & Equivalents is $54.1 million, with a median of $44.4 million in 2022.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Cash & Equivalents tumbled by 9539.23% in 2021, and later surged by 51653.99% in 2022.
  • Enanta Pharmaceuticals' Cash & Equivalents (Quarter) stood at $99.1 million in 2021, then plummeted by 57.38% to $42.2 million in 2022, then dropped by 5.42% to $39.9 million in 2023, then skyrocketed by 111.23% to $84.3 million in 2024, then crashed by 55.62% to $37.4 million in 2025.
  • Its last three reported values are $37.4 million in Q4 2025, $32.3 million for Q3 2025, and $44.8 million during Q2 2025.